21 April, 2017 by The TZ Newswire Staff Comments Off on Why Immunomedics, Inc. Got Hammered Today
Why Immunomedics, Inc. Got Hammered Today
Immunomedics (NASDAQ: IMMU) fell 13% today, after The Fly reported that Immunomedics told an Jefferies analyst that the biotech won’t report data for its cancer drug sacituzumab govitecan, which also goes by the code name IMMU-132, at the American Society of Clinical Oncology meeting in June.
Biotech investors often jump into stocks ahead of data releases and then move on, so it isn’t particularly surprising that the lack of a binary event would cause shares to decline even if it doesn’t change Immunomedics’ underlying valuation.
21 April, 2017 by The TZ Newswire Staff Comments Off on Why Immunomedics, Inc. Got Hammered Today
Why Immunomedics, Inc. Got Hammered Today
Immunomedics (NASDAQ: IMMU) fell 13% today, after The Fly reported that Immunomedics told an Jefferies analyst that the biotech won’t report data for its cancer drug sacituzumab govitecan, which also goes by the code name IMMU-132, at the American Society of Clinical Oncology meeting in June.
Biotech investors often jump into stocks ahead of data releases and then move on, so it isn’t particularly surprising that the lack of a binary event would cause shares to decline even if it doesn’t change Immunomedics’ underlying valuation.
21 April, 2017 by The TZ Newswire Staff Comments Off on Why Briggs & Stratton Stock Climbed 9% Today
Why Briggs & Stratton Stock Climbed 9% Today
Shares of small-engine specialist Briggs & Stratton (NYSE: BGG) ran up as high as 11% before retracing to end the day up 9.4% Friday.
21 April, 2017 by The TZ Newswire Staff Comments Off on 2 Reasons Procter & Gamble Co. Is a Better Dividend Stock Than Kimberly Clark Co.
2 Reasons Procter & Gamble Co. Is a Better Dividend Stock Than Kimberly Clark Co.
Procter & Gamble (NYSE: PG) has one of the longest-running dividend payments on the market thanks to its 60-year streak of consecutive payout boosts. But the stock has dropped off of many income investors’ watchlists after a few years of subpar raises. The consumer goods giant hiked its dividend by less than 1% in 2016, and by just 3% the year before.
Compare that to peer Kimberly-Clark (NYSE: KMB) and its 5% increases in both time periods. Yet for future dividend growth, P&G looks like the better bet for income investors today.
21 April, 2017 by The TZ Newswire Staff Comments Off on Here’s Why Corecept Therapeutics Incorporated Had a Rough Day
Here’s Why Corecept Therapeutics Incorporated Had a Rough Day
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT), a company focused on developing drugs for the treatment of a variety of cortisol hormone related disorders, finished the week down about 14.2% after an 8.8% slide in Friday’s session. A solid fourth-quarter earnings report read more
21 April, 2017 by The TZ Newswire Staff Comments Off on The secret to winning on the stock market is surprisingly simple
The secret to winning on the stock market is surprisingly simple
The secret to winning on the stock market is surprisingly simple
April 21, 2017
http://www.news.com.au/finance/supe…e/news-story/aacc6f5e88e531dfd356d3c37ba5c26e
WHEN most people think about the share market, they envisage a world where investors try to pick which stocks or mutual funds will finish ahead of the pack.
